Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 7/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.54 |
| ▸ | CCNC | P24863 | 9/20 | 0.49 |
| ▸ | CDK8 | P49336 | 9/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | MYLK | Q15746 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | CILK1 | Q9UPZ9 | 1/20 | 0.42 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18321643 | 1.00 | CYP11B2 (0.54) | CYP11B2CYP11B1CCNCCDK8ROCK2 | |
| SCHEMBL18321547 | 0.89 | CYP11B1 (0.55) | CYP11B2CYP11B1CCNCCDK8ROCK2 | |
| SCHEMBL31696890 | 0.89 | CYP11B1 (0.55) | CYP11B2CYP11B1CCNCCDK8ROCK2 | |
| SCHEMBL18321419 | 0.88 | CYP11B1 (0.50) | CYP11B2CYP11B1CCNCCDK8ROCK2 | |
| SCHEMBL31696907 | 0.88 | CYP11B1 (0.50) | CYP11B2CYP11B1CCNCCDK8ROCK2 | |
| SCHEMBL18321464 | 0.80 | TACR1 (0.41) | CYP11B2CYP11B1TACR1 | |
| SCHEMBL31696896 | 0.80 | TACR1 (0.46) | TACR1 | |
| SCHEMBL18321369 | 0.80 | TACR1 (0.46) | TACR1 | |
| SCHEMBL18321651 | 0.78 | FASN (0.51) | TACR1 | |
| SCHEMBL18321582 | 0.77 | FASN (0.50) | CYP11B2CYP11B1NAMPTTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | CEPHALON LLC (US) | 2025-10-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | CYP11B2 270/4885CYP11B1 153/4885CCNC 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.